Royal Bank of Canada
VNDA icon

Royal Bank of Canada’s Vanda Pharmaceuticals VNDA Stock Holding History

Royal Bank of Canada’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,000
Closed -$81K – 6150
2014
Q1 		$81K Hold
5,000
– – ﹤0.01% 4651
2013
Q4 		$62K Buy
+5,000
New +$50.2K ﹤0.01% 4799

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's VNDA Position: Q1 2026 in Review

Royal Bank of Canada sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 1,581 shares — an estimated $14K sold.

Royal Bank of Canada first reported a position in VNDA in Q2 2013 and held it in 50 quarters. The position peaked at $734K in Q3 2013. 171 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Royal Bank of Canada reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 1,581 Vanda Pharmaceuticals shares in Q1 2026, an estimated $14K.
  • Royal Bank of Canada first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Royal Bank of Canada's Vanda Pharmaceuticals position peaked at $734K in Q3 2013.
  • 171 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.